POLQ inhibition elicits an immune response in homologous recombination–deficient pancreatic adenocarcinoma via cGAS/STING signaling

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that harbors mutations in homologous recombination-repair (HR-repair) proteins in 20%-25% of cases. Defects in HR impart a specific vulnerability to poly ADP ribose polymerase inhibitors and platinum-containing chemotherapy in tumor cells. However, not all patients who receive these therapies respond, and many who initially respond ultimately...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytomegalovirus and herpesvirus research
• Share to interferon and immune responses
• Share to PARP inhibition in cancer therapy